Independent predictors of tuberculosis mortality in a high HIV prevalence setting: A retrospective cohort study

AIDS Research and Therapy

Volumn 12, Issue 1, 2015, Pages

  Pepper, Dominique J ^a,b   Schomaker, Michael ^a   Wilkinson, Robert J ^a,c   Azevedo, Virginia ^d   Maartens, Gary ^a,e  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d City Health   (South Africa)

^e UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

HIV; Mortality; Multivariate analysis; Predictors; Tuberculosis

Indexed keywords

ANTIRETROVIRUS AGENT; COTRIMOXAZOLE; TUBERCULOSTATIC AGENT;

ADULT; AGE; ARTICLE; CD4 LYMPHOCYTE COUNT; CHEMOPROPHYLAXIS; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE SURVEILLANCE; EXTRAPULMONARY TUBERCULOSIS; FEMALE; GENDER; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MIXED INFECTION; MORTALITY; PREDICTION; PRIORITY JOURNAL; REGISTER; RETROSPECTIVE STUDY; RISK FACTOR; SOUTH AFRICA; TUBERCULOSIS;

EID: 84943399151     PISSN: None     EISSN: 17426405     Source Type: Journal    
DOI: 10.1186/s12981-015-0076-5     Document Type: Article

References (44)

1. WHO 2012. Global tuberculosis control. 2012. http://whqlibdoc.who.int/publications/2011/9789241564380_eng.pdf. Accessed 1 Sep 2015.
2. Van den Broek J, Mfi nanga S, Moshiro C, O'Brien R, Mugomela A, Lefi M. Impact of human immunodeficiency virus infection on the outcome of treatment and survival of tuberculosis patients in Mwanza, Tanzania. Int J Tuberc Lung Dis. 1998;2:547-52.
3. Kang'ombe C, Harries AD, Banda H, et al. High mortality rates in tuberculosis patients in Zomba Hospital, Malawi, during 32 months of follow-up. Trans R Soc Trop Med Hyg. 2000;94:305-9.
4. Zachariah R, Spielmann MP, Harries AD, Salaniponi FM. Moderate to severe malnutrition in patients with tuberculosis is a risk factor associated with early death. Trans R Soc Trop Med Hyg. 2002;96:291-4.
5. Sacks LV, Pendle S. Factors related to in-hospital deaths in patients with tuberculosis. Arch Intern Med. 1998;158:1916-22.
6. Churchyard GJ, Kleinschmidt I, Corbett EL, Murray J, Smit J, De Cock KM. Factors associated with an increased case-fatality rate in HIV-infected and non-infected South African gold miners with pulmonary tuberculosis. Int J Tuberc Lung Dis. 2000;4:705-12.
7. Connolly C, Davies GR, Wilkinson D. Impact of the human immunodeficiency virus epidemic on mortality among adults with tuberculosis in rural South Africa, 1991-1995. Int J Tuberc Lung Dis. 1998;2:919-25.
8. Gustafson P, Gomes VF, Vieira CS, et al. Clinical predictors for death in HIV-positive and HIV-negative tuberculosis patients in Guinea-Bissau. Infection. 2007;35:69-80.
9. Harries AD, Nyangulu DS, Kangombe C, et al. Treatment outcome of an unselected cohort of tuberculosis patients in relation to human immunodeficiency virus serostatus in Zomba Hospital, Malawi. Trans R Soc Trop Med Hyg. 1998;92:343-7.
10. Kelly PM, Cumming RG, Kaldor JM. HIV and tuberculosis in rural sub-Saharan Africa: a cohort study with two year followup. Trans R Soc Trop Med Hyg. 1999;93:287-93.
11. Cain KP, Anekthananon T, Burapat C. Causes of death in HIV-infected persons who have tuberculosis, Thailand. Emerg Infect Dis. 2009;15:258-64.
12. Murray J, Sonnenberg P, Shearer SC, Godfrey-Faussett P. Human immunodefi ciency virus and the outcome of treatment for new and recurrent pulmonary tuberculosis in African patients. Am J Respir Crit Care Med. 1999;159:733-40.
13. Vasankari T, Holmstrom P, Ollgren J, Liippo K, Kokki M, Ruutu P. Risk factors for poor tuberculosis treatment outcome in Finland: a cohort study. BMC Public Health. 2007;7:291.
14. Hargreaves NJ, Kadzakumanja O, Phiri S, et al. What causes smear-negative pulmonary tuberculosis in Malawi, an area of high HIV prevalence? Int J Tuberc Lung Dis. 2001;5:113-22.
15. Barker RD, Nthangeni ME, Millard FJ. Is the distance a patient lives from hospital a risk factor for death from tuberculosis in rural South Africa? Int J Tuberc Lung Dis. 2002;6:98-103.
16. de Valliere S, Barker RD. Poor performance status is associated with early death in patients with pulmonary tuberculosis. Trans R Soc Trop Med Hyg. 2006;100:681-6.
17. Business Trust and dplg. Khayelitsha Nodal Economic Development Profile. 2007. http://www.btrust.org.za/index.php?id=148&tx_abdownloads_pi1[action]=getviewcatalog&tx_abdownloads_pi1[category_uid]=26&tx_abdownloads_pi1[cid]=120&cHash=064d6b4433. Accessed 1 Sep 2015.
18. South African Department of Health. The South African National Tuberculosis Control Programme Practical Guidelines. 2004. http://www.kznhealth.gov.za/chrp/documents/Guidelines/Guidelines%20National/Tuberculosis/SA%20TB%20Guidelines%202004.pdf. Accessed 1 Sep 2015.
19. Pepper DJ, Marais S, Wilkinson RJ, Bhaijee F, Maartens G, et al. Clinical deterioration during antituberculosis treatment in Africa: incidence, causes and risk factors. BMC Infect Dis. 2010;10:83.
20. Pepper DJ, Marais S, Bhaijee F, Wilkinson RJ, De Azevedo V, et al. Barriers to initiation of antiretrovirals in HIV-infected patients receiving antituberculosis treatment. PLoS One. 2011;6(5):e20077.
21. Pepper DJ, Marais S, Bhaijee F, Wilkinson RJ, De Azevedo V, Meintjes G. Assessment at antiretroviral clinics during tb treatment reduces loss to follow-up among HIV-Infected patients. PLoS One. 2012;7(6):e37634.
22. ETR.NET of South Africa. The Electronic Tuberculosis Register. 2010. http://www.etrnet.info/Default.aspx. Accessed 1 Sep 2015.
23. WHO 1994 World Health Organization. Global tuberculosis programme. A framework for effective tuberculosis control. WHO/TB/94.179. Geneva: WHO; 1994.
24. Rubin D. Multiple imputation after 18+ years. J Am Stat Assoc. 1996;91:473-89.
25. White I, Royston P, Wood A. Multiple imputation using chained equations. Stat Med. 2011;30:377-99.
26. Schomaker M, Heumann C. Model selection and model averaging after multiple imputation. Comput Stat Data Anal. 2014;71:758-70.
27. Cornell M, Schomaker M, Garone DB, Giddy J, Hoffmann CJ, Lessells R, Maskew M, Prozesky H, Wood R, Johnson LF, Egger M, Boulle A, Myer L. Gender differences in survival among adult patients starting antiretroviral therapy in South Africa: a multicentre cohort study. PLoS Med. 2012;9(9):e1001304.
28. Abos-Hernandez R, Olle-Goig JE. Patients hospitalised in Bolivia with pulmonary tuberculosis: risk factors for dying. Int J Tuberc Lung Dis. 2002;6:470-4.
29. Duarte EC, Bierrenbach AL, Barbosa da Silva J Jr, Tauil PL, de Fatima Duarte E. Factors associated with deaths among pulmonary tuberculosis patients: a case-control study with secondary data. J Epidemiol Community Health. 2009;63:233-8.
30. Baussano I, Pivetta E, Vizzini L, Abbona F, Bugiani M. Predicting tuberculosis treatment outcome in a low-incidence area. Int J Tuberc Lung Dis. 2008;12:1441-8.
31. Faustini A, Hall AJ, Mantovani J, Sangalli M, Perucci CA. Treatment outcomes and relapses of pulmonary tuberculosis in Lazio, Italy, 1999-2001: a six-year follow-up study. Int J Infect Dis. 2008;12:611-21.
32. Shen X, Deriemer K, Yuan Z, et al. Deaths among tuberculosis cases in Shanghai, China: who is at risk? BMC Infect Dis. 2009;9:95.
33. Quy HT, Cobelens FG, Lan NT, Buu TN, Lambregts CS, Borgdorff MW. Treatment outcomes by drug resistance and HIV status among tuberculosis patients in Ho Chi Minh City, Vietnam. Int J Tuberc Lung Dis. 2006;10:45-51.
34. Cole SR, Hernán MA, Margolick JB, Cohen MH, Robins JM. Marginal structural models for estimating the effect of highly active antiretroviral therapy initiation. Am J Epidemiol. 2005;162(5):471-8.
35. WHO. TBHIV co-infection: summary of major studies and considerations for 2009 ART guidelines review. 2009. http://www.who.int/hiv/topics/treatment/tbhiv_co-infection_summary_evidence.pdf. Accessed 1 Sep 2015.
36. Pepper DJ, Rebe K, Morroni C, Wilkinson RJ, Meintjes G. Clinical deterioration during antitubercular treatment at a district hospital in South Africa: the importance of drug resistance and AIDS defining illnesses. PLoS One. 2009;4(2):e4520.
37. Pepper DJ, Marais S, Wilkinson RJ, Bhaijee F, Maartens G, McIlleron H, De Azevedo V, Cox H, McDermid C, Sokhela S, Patel J, Meintjes G. Clinical deterioration during antituberculosis treatment in Africa: incidence, causes and risk factors. BMC Infect Dis. 2010;30(10):83.
38. Zachariah R, Spielmann MP, Chinji C, Gomani P, Arendt V, Hargreaves NJ, Salaniponi FM, Harries AD. Voluntary counselling, HIV testing and adjunctive cotrimoxazole reduces mortality in tuberculosis patients in Thyolo, Malawi. AIDS. 2003;17(7):1053-61.
39. Mwaungulu FB, Floyd S, Crampin AC, Kasimba S, Malema S, Kanyongoloka H, Harries AD, Glynn JR, Fine PE. Cotrimoxazole prophylaxis reduces mortality in human immunodeficiency virus-positive tuberculosis patients in Karonga District, Malawi. Bull World Health Organ. 2004;82(5):354-63.
40. Van Cutsem G, Ford N, Hildebrand K, Goemaere E, Mathee S, et al. Correcting for mortality among patients lost to follow up on antiretroviral therapy in South Africa: a cohort analysis. PLoS One. 2011;6(2):e14684.
41. Waitt CJ, Squire SB. A systematic review of risk factors for death in adults during and after tuberculosis treatment. Int J Tuberc Lung Dis. 2011;5:871-85.
42. Deretic V. Autophagy as an immune defense mechanism. Curr Opin Immunol. 2006;18(4):375-82.
43. http://www.mrc.ac.za/bod/faqdeath.htm. What are the top causes of death in South Africa? Accessed 1 Sep 2015.
44. Oni T, Youngblood E, Boulle A, McGrath N, Wilkinson RJ, Levitt NS. Patterns of HIV, TB, and non-communicable disease multi-morbidity in peri-urban South Africa-a cross sectional study. BMC Infect Dis. 2015;17(15):20.